Jim Cramer says the Fed action is great news for high-growth tech stocks, which should be among the first sectors to recover.

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...